The 15-valent conjugate vaccine was at least as effective as Pfizer's 13-valent Prevnar 13 in the study, which involved infants up to 15 months old, and will form the basis of regulatory filing to ...

It covers 15 different pneumococcal serotypes – two more than Pfizer's current Prevnar 13 shot – and has been approved for use in patients aged 18 or over. Pfizer's updated 20-valent vaccine ...

The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, ...

VAX-31’s safety, tolerability, and immunogenicity are being assessed in this trial on healthy infants. Vaxcyte anticipat ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Key pipeline assets include the CDK4 inhibitor, the SV and PD-L1 ADCs, and the next-generation Prevnar vaccine, all of which have the potential to be blockbuster products. Pfizer Inc. (NYSE ...

Prevnar revenues were in line with the Zacks ... The adjusted tax rate is expected to be approximately 15% in 2025. Pfizer’s fourth-quarter results were strong as it beat estimates for earnings ...

Pfizer Inc. (NYSE:PFE – Get Free Report) shares traded up 2.9% on Wednesday following a stronger than expected earnings ...

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 8 includes Lara Exploration, Imperial Oil, Avino ...

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...